Back to search

Peptide record

TPDB20337

Nigrocin-PN Antibacterial Anticancer Antifungal Toxicity standard
21 amino acids
Basic Information
3D PDB MODEL
Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.
TPDB20337
Nigrocin-PN
Antibacterial Anticancer Antifungal Toxicity
Anti-infective peptides Cancer-related peptides Toxicity and safety peptides
Peptipedia CancerPPD 2.0 dbACP ToxinPred 3.0
standard
No
A 21-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from Peptipedia, CancerPPD 2.0, dbACP, and other sources, with an available 3D structural model.
Sequence
GLLGKILGAGKKVLCGVSGLC
Physicochemical Analysis
C88H160N24O23S2
RNDEQHMFPTWY
G
1986.51
9.80
3
0
9
+3
-0.46
1.133
143.81
Mammalian: 30 hour Yeast: >20 hour E.coli: >10 hour
125
6.29
3
Residue Composition
number
1
A
0
R
0
N
0
D
2
C
0
E
0
Q
6
G
0
H
1
I
5
L
3
K
0
M
0
F
0
P
1
S
0
T
0
W
0
Y
2
V
Amino Acid Distribution
A: 1 R: 0 N: 0 D: 0 C: 2 E: 0 Q: 0 G: 6 H: 0 I: 1 L: 5 K: 3 M: 0 F: 0 P: 0 S: 1 T: 0 W: 0 Y: 0 V: 2
Chemical Descriptors
21
C88H160N24O23S2
1986.51
9.80
+3
-0.46
1.133
Free
L
Linear
Free
Antimicrobial and Antitumor
Pelophylax nigromaculatus
Evidence Records 15 records
Evidence 1 Activity

Activity

MIC
Antibacterial
8 µM

Target

S. constellatus B003 VISIT

Source & Reference

NA

Other

493, MRSA B038 V1S1A, MRSA B042 V2E1A (MIC 16-32 uM), E. faecalis NCTC 12,697 (MIC 8 uM), S. constellatus B003 VISIT (MIC 8 uM), Gram- E. coli NCTC 10,418 (MIC 8 uM), K. pneumoniae ATCC 13,883, K. pneumoniae ATCC 43,8
Evidence 2 Activity

Activity

MIC
Antibacterial
64 µM

Target

Pseudomonas aeruginosa ATCC 9097

Source & Reference

NA

Other

pneumoniae ATCC 13,883, K. pneumoniae ATCC 43,816 (MIC 16 uM), P. aeruginosa ATCC 27,853, P. aeruginosa ATCC 9097 (MIC 64 uM), P. aeruginosa B004 V2S2B (MIC 16 uM), and fungus C. albicans NYCY 1467 (MIC 32 uM). Also
Evidence 3 Activity

Activity

MIC
Antibacterial
16 µM

Target

Pseudomonas aeruginosa B004 V2S2B

Source & Reference

NA

Other

ATCC 43,816 (MIC 16 uM), P. aeruginosa ATCC 27,853, P. aeruginosa ATCC 9097 (MIC 64 uM), P. aeruginosa B004 V2S2B (MIC 16 uM), and fungus C. albicans NYCY 1467 (MIC 32 uM). Also showed effects on MRSA biofilms.
Evidence 4 Activity

Activity

MIC
Antibacterial
32 µM

Target

Candida albicans NYCY 1467

Source & Reference

NA

Other

53, P. aeruginosa ATCC 9097 (MIC 64 uM), P. aeruginosa B004 V2S2B (MIC 16 uM), and fungus C. albicans NYCY 1467 (MIC 32 uM). Also showed effects on MRSA biofilms.
Evidence 5 Activity

Activity

IC50
IC50 = 18.04 µM
Anticancer
18.04 µM

Target

Non-small cell lung cancer
H-157
Lung

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2022

Other

Source Activity Label Source Definition
Anticancer
CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.
Evidence 6 Activity

Activity

IC50
IC50 = 53.03 µM
Anticancer
53.03 µM

Target

Prostate cancer
PC-3
Prostate

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2022
Evidence 7 Activity

Activity

IC50
IC50 = 73.65 µM
Anticancer
73.65 µM

Target

Brain Tumor
U-251-MG
Brain

Assay & Model

MTT assay
24-h

Source & Reference

CancerPPD 2.0 dbACP
CancerPPD2
2022
Evidence 8 Activity

Activity

MIC
Antifungal
8 µM

Target

S. constellatus B003 VISIT

Source & Reference

NA

Other

493, MRSA B038 V1S1A, MRSA B042 V2E1A (MIC 16-32 uM), E. faecalis NCTC 12,697 (MIC 8 uM), S. constellatus B003 VISIT (MIC 8 uM), Gram- E. coli NCTC 10,418 (MIC 8 uM), K. pneumoniae ATCC 13,883, K. pneumoniae ATCC 43,8
Evidence 9 Activity

Activity

MIC
Antifungal
64 µM

Target

Pseudomonas aeruginosa ATCC 9097

Source & Reference

NA

Other

pneumoniae ATCC 13,883, K. pneumoniae ATCC 43,816 (MIC 16 uM), P. aeruginosa ATCC 27,853, P. aeruginosa ATCC 9097 (MIC 64 uM), P. aeruginosa B004 V2S2B (MIC 16 uM), and fungus C. albicans NYCY 1467 (MIC 32 uM). Also
Evidence 10 Activity

Activity

MIC
Antifungal
16 µM

Target

Pseudomonas aeruginosa B004 V2S2B

Source & Reference

NA

Other

ATCC 43,816 (MIC 16 uM), P. aeruginosa ATCC 27,853, P. aeruginosa ATCC 9097 (MIC 64 uM), P. aeruginosa B004 V2S2B (MIC 16 uM), and fungus C. albicans NYCY 1467 (MIC 32 uM). Also showed effects on MRSA biofilms.
Evidence 11 Activity

Activity

MIC
Antifungal
32 µM

Target

Candida albicans NYCY 1467

Source & Reference

NA

Other

53, P. aeruginosa ATCC 9097 (MIC 64 uM), P. aeruginosa B004 V2S2B (MIC 16 uM), and fungus C. albicans NYCY 1467 (MIC 32 uM). Also showed effects on MRSA biofilms.
Evidence 12 Activity

Activity

<5% Hemolysis
Toxicity
100 µM
Hemolytic Cytotoxic
<5% Hemolysis | 100 | µM | target cell: Horse erythrocytes

Target

Horse erythrocytes

Source & Reference

NA
DBAASP
A novel antimicrobial peptide found in Pelophylax nigromaculatus | J Genet Eng Biotechnol | 2022
Evidence 13 Activity

Activity

LC50
Toxicity
80 µM
Cytotoxic
LC50 | 80 | µM | target cell: Human keratinocytes HaCat

Target

Human keratinocytes HaCat

Source & Reference

NA
DBAASP
A novel antimicrobial peptide found in Pelophylax nigromaculatus | J Genet Eng Biotechnol | 2022
Evidence 14 Activity

Activity

Toxicity
Cytotoxic
NA | target cell: Human microvascular endothelial cells HMEC-1

Target

Human microvascular endothelial cells HMEC-1

Source & Reference

NA
DBAASP
Evidence 15 Activity

Activity

Toxicity
Hemolytic Cytotoxic
Hemolytic_activity: Not available | Cytotoxicity: Not available

Target

erythrocytes

Source & Reference

NA
DRAMP
J Genet Eng Biotechnol. 2022 May 23 20(1):76.